NCT03761914COMPLETEDanonymous

A Phase 1/2 Study of Galinpepimut-S in Combination With Pembrolizumab (MK 3475) in Patients With Selected Advanced Cancers

Sponsor

Source record

Sellas Life Sciences Group

Phase

Source record

PHASE1

Modality

AI-normalized

monoclonal antibody

Target

AI-normalized

galinpepimut-S, pembrolizumab, Montanide, GM-CSF

Indication / condition

AI-normalized

Acute Myelogenous Leukemia

Intervention

Source record

galinpepimut-S, pembrolizumab, Montanide, GM-CSF

Source & freshness

Source record

NCT ID

NCT03761914

Original source

ClinicalTrials.gov

Source last updated

Nov 19, 2024

Ingested at

Jun 09, 2026

Internal sync

Jun 09, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT03761914

Title

A Phase 1/2 Study of Galinpepimut-S in Combination With Pembrolizumab (MK 3475) in Patients With Selected Advanced Cancers

Sponsor

Sellas Life Sciences Group

Status

COMPLETED

Phase

PHASE1

Condition raw

Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer, Small-cell Lung Cancer

Condition normalized

Acute Myelogenous Leukemia, Ovarian Cancer, Colorectal Cancer, Triple-negative Breast Cancer, Small-cell Lung Cancer

Modality raw

monoclonal antibody

Modality normalized

monoclonal antibody

Target raw

galinpepimut-S, pembrolizumab, Montanide, GM-CSF

Target normalized

galinpepimut-S, pembrolizumab, Montanide, GM-CSF

Interventions

galinpepimut-S, pembrolizumab, Montanide, GM-CSF

Public preview

Source record

To evaluate the safety, tolerability, and anti-tumor activity of galinpepimut-S in combination with pembrolizumab in patients with selected advanced cancers.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

A Phase 1/2 Study of Galinpepimut-S in Combination With Pembrolizumab (MK 3475) in Patients With Selected Advanced Cancers

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 13, 2026

NCT ID

NCT03761914

Status

COMPLETED

Phase

PHASE1

Sponsor

Sellas Life Sciences Group

Executive brief

Investment-Ready Snapshot

To evaluate the safety, tolerability, and anti-tumor activity of galinpepimut-S in combination with pembrolizumab in patients with selected advanced cancers.

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedNov 19, 2024

Internal syncJun 09, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT03761914

Indication

Acute Myelogenous Leukemia

Modality

monoclonal antibody

Target

galinpepimut-S, pembrolizumab, Montanide, GM-CSF

Intervention

galinpepimut-S, pembrolizumab, Montanide, GM-CSF

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.